





































Can Peripheral Nerve Blocks Improve Patients’ Outcomes in
Adults With Hip Fracture?
A Cochrane Review Summary With Commentary on Implications for
Practice in Rehabilitation
Francesca Cecchi, MD
T he aim of this commentary is to discuss from a rehabilita-tion perspective the published Cochrane Review “Periph-
eral nerve blocks for hip fractures in adults” by Guay and
Kopps1 (https://www.cochranelibrary.com/cdsr/doi/10.1002/
14651858.CD001159.pub3/full), under the direct supervision
of Cochrane Review Group. This Cochrane Corner is pro-
duced in agreement with the American Journal of PM&R by
Cochrane Rehabilitation.
BACKGROUND
Hip fractures (HFs) are associated with functional decline,
worsened quality of life, and high mortality rates; their inci-
dence increases exponentially with age, and their worldwide
annual incidence is expected to reach 4.5 million by 2050 (Na-
tional Hip Fracture database 2019, http://www.nhfd.co.uk),
with increasing direct and indirect costs. Severe pain is a clin-
ical feature of HF that associates with worse clinical and func-
tional outcomes, such as delayed mobilization, longer hospital
stay, worse quality of life, and higher delirium rates; the onset
of delirium after HF is also independently associated with de-
mentia, institutionalization, and mortality.2 Although there is
consistent evidence that effective analgesia reduces delirium
in HFs, pain in elderly HF patients is still undertreated. Indeed,
HFs often select frail elderly patients who are more likely to
have impaired abilities to communicate pain and are more
vulnerable to drug-related adverse events. Actually, in sec-
ond line to paracetamol, opioids are consistently recom-
mended for HF preoperative and postoperative pain control,
but elderly frail patients are at higher risk of opioid accumula-
tion, and this, in turn,may lead to respiratory depression, hypoxia,
pulmonary infections, increasing risk of brain damage, and
death.3 Opioids have been also associated with delirium, as well
as undertreated pain, thus balancing opioids’ administration in
this population is often a complex clinical challenge.
In search of better options to provide both safe and effec-
tive analgesia to HF patients, increasing attention has then fo-
cused on regional anesthesia and analgesia, either as an
alternative or an adjunct to systemic analgesia. Regional block-
ade refers to injection of local anesthetic around neural struc-
tures, to temporarily interrupt nociceptive transmission to the
brain; in peripheral nerve blocks (PNBs) the local anesthetic
is applied around the nerves. Peripheral nerve blocks are used
both as a replacement for general anesthesia during surgery
and as adjunctive treatment for perioperative pain, and they
may be delivered either as a single-injection or as a prolonged
infusion though a catheter. Peripheral nerve blocks provide
site-specific and rapid analgesia and may reduce the need of
systemic antalgic therapy: a 2017 Cochrane review, updating
previous works on the effects of PNBs in adults with HF, re-
ported high-quality evidence of PNBs to reduce pain on
movement within 30 mins of injection; moderate-quality evi-
dence of reduced risk for chest infections, decreased time to
first mobilization, and cost reduction of the analgesic regimen
for single-injection blocks was also reported, whereas insuffi-
cient information was found for acute confusional state, myo-
cardial ischemia, and death within 6 mos from HFs.4 The
International Societies Guidelines have been recently published,
recommending the use of PNBs in treating HF patients’ pain,
but this practice is still not as widespread than recommended.
For all these reasons, an update of the former Cochrane review
was deemed necessary.
Any intervention reducing pain, delirium, and other
clinical complications after HF is highly relevant to short-
and long-term HF rehabilitation outcomes. Indeed, despite
progress in surgery, clinical care, and rehabilitation path-
ways, HF is still a catastrophic event, burdened with a high
risk of mortality and residual disability: approximately one
third of HF patients are institutionalized, and approximately half
of them experience a permanent postfracture disability, whereas
most report a worsened quality of life.5 Clinical complexity and
chronic and acute cognitive impairment predict rehabilitation
failure, thus identifying care pathways that reduce clinical com-
plications and improve mobility of HP fracture patients, while
containing direct and indirect HF costs, is of vital importance
to potentially improve rehabilitation processes and outcomes.6
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PERIPHERAL NERVE BLOCKS FOR HIP
FRACTURES IN ADULTS
What Is the Aim of This Cochrane Review?
The aim of this Cochrane review was to update previous
reviews comparing PNBs used as preoperative analgesia, as
postoperative analgesia, or as an adjunct to general anesthesia
versus no nerve block or sham block for adults with HF.
What Was Studied in the Cochrane Review?
The population addressed in this review included was
adults (age >16) and older adults. The interventions studied
were PNBs, used as preoperative analgesia, as postoperative
analgesia, or as a supplement to general anesthesia. The inter-
vention was compared with no nerve block or sham block.
The outcomes studied were pain on movement at 30 mins after
block placement; the occurrence 0–30 days of acute confu-
sional state, myocardial infarction, and chest infection; and
death within 6 mos from HF, time to first mobilization, and
costs of an analgesic regimen for single-injection blocks.
Search Methodology and Up-To-Dateness of the
Cochrane Review?
The review authors searched for studies that had been pub-
lished up to November 2019 in the Cochrane Central Register
of Controlled Trials (CENTRAL, 2019, Issue 11), the
Cochrane Library, MEDLINE (Ovid SP, 1966 to November
2019), Embase (Ovid SP, 1974 to November 2019), and the
Cumulative Index to Nursing and Allied Health Literature
(EBSCO, 1982 to November 2019). They also searched trial
registers and reference lists of relevant articles. Only random-
ized controlled trials comparing use of PNBs with no nerve
block (or sham block) for persons 16 yrs and older with HF
were included. The certainty of evidence was rated using the
Grading of Recommendations, Assessment, Development and
Evaluations approach.
What Are the Main Results of the
Cochrane Review?
The authors included 49 studies (3061 participants: 1553
randomized to PNBs and 1508 to no nerve block [or sham
block] vs. 31 trials and 1760 participants of the former 2017 re-
view). Participants’ age ranged from 59 to 89 yrs; most trials
excluded patients with dementia.
The review reports high-certainty evidence that PNBs
reduced:
• Pain on movement within 30 mins of block placement, by
2.5 points on a 0- to 10-pain scale on average, with an effect
size that was proportionate to the concentration of local
anesthetic
• The risk of acute confusional state (1 person less over 12
treated for HF will become confused with PNBs)
Moderate-certainty evidence was found for PNBs to reduce:
• Chest infection (1 person less over 7 treated for HF will de-
velop chest infection with PNBs)
• Time to first mobilization (by 10 hours on average)
Because of few studies and reduced number of participants,
only low-certainty evidence was found as to PNBs reducing:
• The risk of myocardial infarction
• Mortality within 6 mos
• The cost of analgesic regimen for single-injection block
(only one trial, small reduction for single-injection block)
How Did the Authors Conclude?
The authors concluded PNBs reduce pain on movement
within 30 mins after block placement and risk of acute confu-
sional state and probably also reduce the risk of chest infection
and time to first mobilization. There may be a small reduction
in the cost of analgesic drugs for single-injection PNBs.
As the numbers of participants were insufficient, only
low-quality evidence suggested a PNBs’ associated reduction
of myocardial infarction and mortality. The authors also state
that their review confirms other finding of low risks of perma-
nent injury associated with PNBs, although randomized con-
trolled trials are not the most appropriate study design to the
purpose of investigating this issue. In their opinion, although
high-quality nonrandomized studies are recommended to fur-
ther clarify the relationship of PNBs with myocardial infarc-
tion and death in this population, “it is unclear whether any
further randomized controlled trials should be registered, given
the benefits found.”
What Are the Implications of the Cochrane
Evidence for Practice in Rehabilitation?
Rehabilitation is crucial for the functional recovery of el-
derly patients with HF, and the key contribution of clinical
complexity and care processes to the final functional outcome
has been acknowledged: comorbidity, particularly pain and
acute/chronic cognitive impairment, is consistently associated
with worse rehabilitation outcomes; severe pain carries higher
risks of clinical complications, including delirium. Both pain
and delirium may also delay mobilization and impair communi-
cation, reducing HF patients’ participation to their rehabilitation
process.5,6 Thus, any effort to improve HF operative and periop-
erative pain control may achieve better short as well and
long-term functional outcomes, while mitigating HF-related de-
terioration of quality of life.
This review states that there is now consistent high-quality
evidence that PNBs, used preoperatively, postoperatively, and
in adjunct to systemic analgesia for adults with HP, may not
only reduce pain associated with HF 30 mins after block plac-
ing, but also, probably by better pain control, PNBs reduce the
risk of the occurrence of acute confusional state within 30 days
from HF, while probably reducing also time to first mobiliza-
tion, risk of chest infection within 30 days from HF, and cost
of antalgic treatment for single-shot block.
Actually, the authors come to the statement that in view of
existing evidence for the benefits of PNBs, they no longer con-
siderate appropriate to propose placebo or sham intervention
instead of PNBs, when this procedure is indicated, accepted
by the patient and available, and are thus reluctant to encourage
any further randomized controlled trial on this specific
topic. On the other hand, they support further research by
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good-quality nonrandomized studies to further investigate the
effects of PNBs on myocardial infarction and mortality.
In the face of this mounting evidence, the recent official
recommendation by the National and International Societies
of Anesthetists and Orthopedic Surgeons is further supported,
but their translation into clinical practice has still no easy
way. Clinical decision needs to be judged on a case-by-case ba-
sis, but, overall, the risk of permanent injury associated with
PNBs, especially if performed with ultrasound guidance,
seems to be low. Thus, the reasons for this delay are probably
more related to organizational problems, such as the availabil-
ity of trained staff and equipment, including regional blockade
kits, in the emergency department, and also to cultural/
behavioral barriers to provide a systematic and reliable pain as-
sessment, especially in elderly patients with cognitive and/or
communication impairment, and to shift from the common
practice of exclusive reliance on parenteral and oral opioids
to treat acute pain in the elderly patients. Targeted education
and training programs, as well as definition of integrated care
pathways for treating pain in elderly HF patients, are needed
to effectively translate evidence-based recommendations into
the integration of PNBs into routine multimodal acute pain
management protocols for HFs.7
Although this change will progressively take place, PNBs
widespread use in HF patients promises to deeply affect reha-
bilitation processes and outcomes: improved perioperative
and operative pain control, while probably reducing systemic
analgesia, the occurrence of delirium, and probably chest in-
fection within 30 days from HF, in the time frame when
intensive postacute rehabilitation generally achieves most of
its goals, whereas the likely reduction of time to first mobiliza-
tion may accelerate the rehabilitation process. All these bene-
fits of PNBs can improve HF patients’ participation in
rehabilitation and increase their probability of reaching higher
function and quality of life in a shorter time and at lower costs.
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